Atypical antipsychotics in first trimester may not increase risk for congenital defects

“This landmark report, with the largest population of women exposed to [antipsychotics] published to date to our knowledge, demonstrates that exposure to [antipsychotics] (other than risperidone) does not significantly increase the risk for birth defects, which has been a major source of concern for women and prescribers,” Katherine L. Wisner, MD, MS, of Northwestern University Feinberg School of Medicine, Chicago, and colleagues wrote in an accompanying editorial.

“This publication is timely, given the revision of the FDA Pregnancy and Lactation Labeling Final Rule…Nowhere in medicine is the need for personalization of care so crucial than during pregnancy: personalization of the treatment for serious mental illness with consideration of pregnancy physiology and the mother’s capacity to provide sustenance for the growing fetus and newborn.”


Full article available here: